Cougar Biotechnology, Inc.
Cougar Biotechnology has joined the fight against one beastly predator -- cancer. The development-stage company acquires and develops drug candidates for treating prostate cancer, as well as cancer affecting the blood, bone marrow, and lymph nodes. It has three candidates in early stages of development, and one that has reached the final stages of drug trials. Cougar specializes in moving candidates through development to regulatory approval. As its late-stage compound reached closer to commercial development, Cougar decided the time was right to merge with a larger entity and was acquired by Johnson & Johnson in 2009.
Contact Details
Executives
President, CEO, and Director
Alan H. Auerbach
SVP Finance and Treasurer
Charles R. Eyler